Sector Update: Health Care Stocks Retreat This Afternoon
4:04PM ET 1/21/2022 MT NewswiresHealth care stocks were ending mostly lower this afternoon, with the NYSE Health Care Index falling 0.9% and the SPDR Health Care Select Sector ETF (XLV)...
Quotes Snapshot > APDN
Applied DNA Sciences Inc APDN:NASDAQ
Last Price$3.49NASDAQ Previous Close - Last Trade as of 3:46PM ET 1/26/22
Today's Change-0.01(0.29%)
Bid (Size)$3.32 (1)
Ask (Size)$3.70 (1)
Day Low / High$3.38 - 3.59
Volume55.4 K
Read more news Recent News
Sector Update: Health Care Stocks Drifting Lower in Friday Trade
1:07PM ET 1/21/2022 MT NewswiresHealth care stocks were mostly lower this afternoon, with the NYSE Health Care Index falling 0.4%, while the SPDR Health Care Select Sector ETF (XLV) was...
Applied DNA Unit Seeks US FDA Emergency Use Authorization for RT-PCR COVID-19 Test, Home Collection Kit
10:38AM ET 1/21/2022 MT NewswiresApplied DNA Sciences (APDN) said Friday its Applied DNA Clinical Labs unit filed a request with the US Food and Drug Administration for emergency use...
Applied DNA Sciences' COVID-19 Test Gets Conditional Approval in New York
9:52AM ET 1/04/2022 MT NewswiresApplied DNA Sciences Inc (APDN) said Tuesday the New York State Department of Health has given conditional approval to its unit Applied DNA Clinical Labs...
View all Commentary and Analysis
Flora Ready To Grow Like A Weed
2:43PM ET 1/03/2022 Seeking AlphaApplied DNA Sciences, Inc. (APDN) CEO James Hayward on Q4 2021 Results - Earnings Call Transcript
1:56AM ET 12/10/2021 Seeking AlphaApplied DNA Sciences, Inc. 2021 Q2 - Results - Earnings Call Presentation
9:27AM ET 8/13/2021 Seeking AlphaApplied DNA Sciences, Inc. (APDN) CEO James Hayward on Q3 2021 Results - Earnings Call Transcript
11:11PM ET 8/12/2021 Seeking AlphaCompany Profile
Business DescriptionApplied DNA Sciences, Inc. engages in the developing and marketing DNA-based technology solutions utilizing LinearDNA, large-scale polymerase chain reaction (PCR) based manufacturing platform. Its proprietary platform produces large quantities of DNA for use in nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets (Biotherapeutic Contract Research and Manufacturing) and for supply chain security, anti-counterfeiting and anti-theft technology purposes. The company was founded in 1983 and is headquartered in Stony Brook, NY. View company web site for more details
| Address | 50 Health Sciences Drive Stony Brook, New York 11790 |
| Phone | +1.631.240.8800 |
| Number of Employees | 59 |
| Recent SEC Filing | 01/13/2022 SC 13G/A |
| Chairman, President & Chief Executive Officer | James A. Hayward |
| Chief Operating Officer | Judy Murrah |
| Chief Financial Officer & Controller | Beth M. Jantzen |
| Vice President-Strategic Sales | Wayne Buchen |
Company Highlights
| Price Open | $3.56 |
| Previous Close | $3.49 |
| 52 Week Range | $3.17 - 13.64 |
| Market Capitalization | $26.1 M |
| Shares Outstanding | 7.5 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/10/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.93 |
| Beta vs. S&P 500 | N/A |
| Revenue | $3.9 M |
| Net Profit Margin | -158.25% |
| Return on Equity | -111.92% |
Analyst Ratings as of 02/12/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |